

# Soheil Tavakolpour

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5633597/soheil-tavakolpour-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94  
papers

921  
citations

16  
h-index

26  
g-index

97  
ext. papers

1,294  
ext. citations

3  
avg, IF

5.62  
L-index

#	Paper	IF	Citations
94	Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus. <i>International Journal of Dermatology</i> , <b>2022</b> , 61, e14-e17	1.7	0
93	Retrospective study of gingival involvement in pemphigus: a difficult to treat phenomenon.. <i>Dermatologic Therapy</i> , <b>2022</b> , e15475	2.2	1
92	Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, double-blind, placebo-controlled trial. <i>Journal of Cosmetic Dermatology</i> , <b>2021</b> , 20, 2498-2506	2.5	1
91	Drug-induced pemphigus: A systematic review of 170 patients. <i>International Immunopharmacology</i> , <b>2021</b> , 92, 107299	5.8	12
90	Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, e2	4	0
89	Fatal Outcome of Rituximab in an ANCA Negative Granulomatosis with Polyangiitis Patient with Acute Pancreatitis and Pancreatic Mass. <i>Current Rheumatology Reviews</i> , <b>2021</b> , 17, 2-3	1.6	2
88	Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls. <i>Dermatology Practical and Conceptual</i> , <b>2021</b> , 11, e2021035	1.5	
87	Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1098-1100	4.5	13
86	Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. <i>Genomics</i> , <b>2021</b> , 113, 1221-1232	4.3	64
85	Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14633	2.2	4
84	Lichen planus-like lesions in 36 patients with pemphigus: A cross-sectional study. <i>Oral Diseases</i> , <b>2021</b> , 27, 947-951	3.5	1
83	A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. <i>Infectious Diseases</i> , <b>2021</b> , 53, 315-324	3.1	11
82	A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. <i>Immunopharmacology and Immunotoxicology</i> , <b>2021</b> , 43, 507-518	3.2	8
81	Current status and prospects for the diagnosis of pemphigus vulgaris. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 819-834	5.1	1
80	The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?. <i>Current Rheumatology Reviews</i> , <b>2021</b> , 17, 327-330	1.6	0
79	Evaluating the risk-to-benefit ratio of using cotrimoxazole as a Pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients. <i>Dermatologic Therapy</i> , <b>2021</b> , e15257	2.2	0
78	Concomitant bullous pemphigoid and palmoplantar keratoderma: A report of three cases and review of literature. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14481	2.2	1

77	Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. <i>BMC Dermatology</i> , <b>2020</b> , 20, 13	2.1	1
76	Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-7	2.8	8
75	Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-6	2.8	5
74	Pathogenic and protective roles of cytokines in pemphigus: A systematic review. <i>Cytokine</i> , <b>2020</b> , 129, 155026	4	13
73	Switching from pemphigus vulgaris to psoriasis: a rare report of three cases. <i>International Journal of Dermatology</i> , <b>2020</b> , 59, e144-e146	1.7	1
72	Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. <i>Immunopharmacology and Immunotoxicology</i> , <b>2020</b> , 42, 56-58	3.2	12
71	Desquamative gingivitis in a pemphigus vulgaris patient resistant to rituximab. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13225	2.2	4
70	The Roles of CD4+ T-Cells in Tumor Immunity <b>2020</b> , 63-90		
69	Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies. <i>Current Rheumatology Reviews</i> , <b>2020</b> , 16, 257-266	1.6	2
68	Sofosbuvir for the Treatment of COVID-19 Patients: Is It a Promising Therapeutic Medicine for the Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2?. <i>Avicenna Journal of Medical Biochemistry</i> , <b>2020</b> , 8, 133-135	0.4	
67	Multiple giant milia in cutaneous squamous cell carcinoma: A rare presentation. <i>Australasian Journal of Dermatology</i> , <b>2020</b> , 61, 163-164	1.3	
66	Rituximab monotherapy in mild pemphigus. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-3	2.8	
65	Lymphopenia during the COVID-19 infection: What it shows and what can be learned. <i>Immunology Letters</i> , <b>2020</b> , 225, 31-32	4.1	123
64	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. <i>Reviews in Medical Virology</i> , <b>2020</b> , 30, 1-13	11.7	12
63	Decreased serum levels of interleukin-17, interleukin-23, TGF- $\beta$ in pemphigus vulgaris patients, and their association with disease phase. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14071	2.2	1
62	Treatment of pemphigus patients in the COVID-19 era: A specific focus on rituximab. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14188	2.2	3
61	Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital. <i>International Immunopharmacology</i> , <b>2020</b> , 89, 107093	5.8	2
60	Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14380	2.2	2

59	Comparing efficacy and safety of potassium hydroxide 5% solution with 5-fluorouracil cream in patients with actinic keratoses: a randomized controlled trial. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-7	2.8	1
58	Transition between pemphigus vulgaris and pemphigus foliaceus: a 10-year follow-up study. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 1302-1304	1.2	2
57	Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. <i>International Journal of Immunogenetics</i> , <b>2020</b> , 47, 41-49	2.3	9
56	Treatment of port wine stains with 595-nm pulsed dye laser in 27 pediatric patients: A prospective study in the Iranian population. <i>Journal of Cosmetic and Laser Therapy</i> , <b>2019</b> , 21, 373-377	1.8	8
55	"Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran": A multiple cross-sectional study. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e12827	2.2	1
54	Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment. <i>International Journal of Womens Dermatology</i> , <b>2019</b> , 5, 116-123	2	21
53	The elevated level of osteopontin in patients with pemphigus vulgaris: A cytokine-like protein with a therapeutic potential. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e12973	2.2	2
52	Otophyma in a woman: A rare and neglected clinicopathological entity. <i>Australasian Journal of Dermatology</i> , <b>2019</b> , 60, e337-e338	1.3	3
51	Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases. <i>International Immunopharmacology</i> , <b>2019</b> , 71, 40-42	5.8	12
50	Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, e51-e52	4.5	9
49	Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 346-349	2.8	8
48	A comprehensive review of rituximab therapy in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2977-2994	3.9	29
47	Reply to: "Comment on Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris". <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, e141	4.5	
46	Iranian guideline for rituximab therapy in pemphigus patients. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e13016	2.2	16
45	Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab. <i>International Journal of Womens Dermatology</i> , <b>2019</b> , 5, 372-377	2	5
44	Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 197-212	5.2	5
43	A case of hidroacanthoma simplex with new dermoscopic features. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , <b>2019</b> , 85, 319-321	0.8	1
42	Köbner Phenomenon in a Rituximab-Treated Pemphigus Patient: Beware Disease Activity. <i>Dermatology Practical and Conceptual</i> , <b>2019</b> , 9, 320-321	1.5	

41	Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis). <i>International Immunopharmacology</i> , <b>2019</b> , 70, 67-68	5.8	1
40	Evaluation of the possible association between acantholysis and anti-desmogleins 1 and 3 values in pemphigus vulgaris and pemphigus foliaceus. <i>Journal of Cutaneous Immunology and Allergy</i> , <b>2019</b> , 2, 169-173	0.3	2
39	Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 598-604	2.8	21
38	Post-orf epidermolysis bullosa acquisita. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, e118-e119	4.6	0
37	Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?. <i>Archives of Dermatological Research</i> , <b>2019</b> , 311, 63-69	3.3	18
36	Oral Candida colonization and plaque type psoriasis: Is there any relationship?. <i>Journal of Investigative and Clinical Dentistry</i> , <b>2018</b> , 9, e12335	2.3	6
35	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. <i>Infectious Diseases</i> , <b>2018</b> , 50, 95-106	3.1	15
34	Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases. <i>Clinical Genetics</i> , <b>2018</b> , 93, 481-497	4	17
33	Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. <i>Archives of Dermatological Research</i> , <b>2018</b> , 310, 95-106	3.3	29
32	Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. <i>International Immunopharmacology</i> , <b>2018</b> , 54, 131-138	5.8	47
31	Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial. <i>International Journal of Womens Dermatology</i> , <b>2018</b> , 4, 87-90	2	6
30	Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. <i>Dermatologic Therapy</i> , <b>2018</b> , 31, e12671	2.2	11
29	Coexistence of oral lichen planus and pemphigus vulgaris. <i>Clinical Oral Investigations</i> , <b>2018</b> , 22, 2953-2955	4.2	4
28	Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. <i>Dermatologic Therapy</i> , <b>2018</b> , 31, e12696	2.2	11
27	Regulatory Responses during Chronic Hepatitis B Virus Infection. <i>Scandinavian Journal of Immunology</i> , <b>2017</b> , 85, 236-237	3.4	1
26	The ignored roles of microRNAs in alopecia areata. <i>Dermatologic Therapy</i> , <b>2017</b> , 30, e12488	2.2	3
25	Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. <i>International Immunopharmacology</i> , <b>2017</b> , 53, 133-142	5.8	32
24	Skin Cancer: Genetics, Immunology, Treatments, and Psychological Care <b>2017</b> , 851-934		8

23	Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. <i>Immunology Letters</i> , <b>2017</b> , 190, 206-212	4.1	4
22	Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges. <i>Immunology Letters</i> , <b>2017</b> , 190, 130-138	4.1	19
21	Management of pemphigus disease in pregnancy. <i>American Journal of Reproductive Immunology</i> , <b>2017</b> , 77, e12601	3.8	13
20	The possible role of interleukin-35 and its therapeutic potential in pemphigus. <i>International Immunopharmacology</i> , <b>2017</b> , 42, 11-17	5.8	9
19	Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection. <i>Dermatology Online Journal</i> , <b>2017</b> , 23,	1	1
18	Interleukin 4 inhibition as a potential therapeutic in pemphigus. <i>Cytokine</i> , <b>2016</b> , 77, 189-95	4	41
17	The dual nature of retinoic acid in pemphigus and its therapeutic potential: Special focus on all-trans Retinoic Acid. <i>International Immunopharmacology</i> , <b>2016</b> , 36, 180-186	5.8	9
16	Blockage of T Cell Activation via Anti-CD40 and Anti-CD154 Monoclonal Antibodies can Possibility Treat Alopecia Areata. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 83, 463-4	3.4	6
15	Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. <i>Immunology Letters</i> , <b>2016</b> , 171, 70-1	4.1	10
14	Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?. <i>International Immunopharmacology</i> , <b>2016</b> , 34, 139-145	5.8	18
13	Comparison of Vitamin D Levels in Naive, Treated, and Inactive Carriers with Chronic Hepatitis B Virus. <i>Journal of Clinical and Translational Hepatology</i> , <b>2016</b> , 4, 306-309	5.2	3
12	Changes in induced regulatory T cells by interleukin 35 during atopic dermatitis. <i>Anais Brasileiros De Dermatologia</i> , <b>2016</b> , 91, 703	1.6	1
11	The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature. <i>Journal of Research in Medical Sciences</i> , <b>2016</b> , 21, 37	1.6	13
10	Tumor Necrosis Factor- $\beta$ 8 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis. <i>Hepatitis Monthly</i> , <b>2016</b> , 16, e33537	1.8	5
9	Association of Plasma Levels of Vitamin D With Chronic Hepatitis B Infection. <i>Hepatitis Monthly</i> , <b>2016</b> , 16, e35525	1.8	2
8	Manipulation of Regulatory Cells Responses to Treatments for Chronic Hepatitis B Virus Infection. <i>Hepatitis Monthly</i> , <b>2016</b> , 16, e37927	1.8	7
7	Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. <i>Hepatitis Monthly</i> , <b>2016</b> , 16, e35810	1.8	25
6	Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. <i>Dermatologic Therapy</i> , <b>2016</b> , 29, 299	2.2	15

5	Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 83, 345-6	3-4	6
4	Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 8, 66-73	4	13
3	The new insight into management of hepatitis B virus patients with flare. <i>Immunology Letters</i> , <b>2016</b> , 173, 77	4-1	7
2	New Insights into the Management of Patients with Autoimmune Diseases or Inflammatory Disorders During Pregnancy. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 84, 146-9	3-4	19
1	Complex Interaction Between Diphenylcyclopropenone and Immune Responses in Alopecia Areata. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 84, 310-311	3-4	3